CLINICAL_TRIALS
trial_result
· 2023-03-21
Clinical Trial Update: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer [Phase 2]
Summary
Phase 2 study of the MET kinase inhibitor INC280 (epernestib) in papillary renal cell cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-03-21